1103 Results for "

Bioavailability

" in MedChemExpress (MCE) Product Catalog:
Products (1103)

1103 Results for "Bioavailability" in MCE Product Catalog:

7
7 Cited Publications
Cat. No.: HY-12599
CAS No.: 1229582-33-5
Purity:  99.34%
Research Areas:  

Neurological Disease Cancer

URMC-099 is an orally bioavailable and potent mixed lineage kinase type 3 (MLK3) (IC50=14 nM) inhibitor with with excellent blood-brain barrier penetration properties.
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-101340
CAS No.: 1610759-22-2
Purity:  99.77%
Synonyms: CFI-402257
Target:  

Mps1

Research Areas:  

Cancer

CFI-402257 is a highly selective and orally bioavailable TTK/Mps1 inhibitor with an IC50 of 1.7 nM for TTK in vitro. CFI-402257 has anti-cancer activity .
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-101340A
CAS No.: 1610677-37-6
Purity:  98.91%
Synonyms: CFI-402257 hydrochloride
Target:  

Mps1

Research Areas:  

Cancer

CFI-402257 hydrochloride is a highly selective and orally bioavailable TTK/Mps1 inhibitor with an IC50 of 1.7 nM for TTK in vitro. CFI-402257 hydrochloride has anti-cancer activity .
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-112287
CAS No.: 2095719-90-5
Purity:  99.58%
Target:  

ERK

Research Areas:  

Cancer

ERK1/2 inhibitor 1 is a potent, orally bioavailable ERK1/2 inhibitor, showing 60% inhibition at 1 nM and an IC50 of 3.0 nM against ERK1 and ERK2, respectively .
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-19327
CAS No.: 1375465-91-0
Target:  

HDAC

Research Areas:  

Cancer

ACY-738 is a potent, selective and orally-bioavailable HDAC6 inhibitor, with an IC50 of 1.7 nM; ACY-738 also inhibits HDAC1, HDAC2, and HDAC3, with IC50s of 94, 128, and 218 nM.
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-135985
CAS No.: 2222635-15-4
Purity:  99.35%
Target:  

Fluorescent Dye

Research Areas:  

Cancer

DCLK1-IN-1 is a selective, oral bioavailability in vivo-compatible chemical probe of the doublecortin like kinase 1 (DCLK1 kinase) domain. DCLK1-IN-1 inhibits DCLK1 and DCLK2 kinases (IC50: DCLK1=9.5/57.2 nM and DCLK2=31/103 nM in binding and kinase assay, respectively). DCLK1-IN-1 shows low toxicity, and can investigate DCLK1 biology and establish its role in cancer, like DCLK1 + pancreatic ductal adenocarcinoma (PDAC) .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-19324
CAS No.: 2095161-11-6
Research Areas:  

Cancer

EPZ031686 is an potent and orally active SMYD3 inhibitor and with an IC50 value of 3 nM. EPZ031686 can be used for cancer research .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-112167A
CAS No.: 1657014-42-0
Purity:  99.32%
Synonyms: ARRY-575 dihydrochloride; RG7741 dihydrochloride
Research Areas:  

Cancer

GDC-0575 dihydrochloride (ARRY-575 dihydrochloride) is an orally bioavailable CHK1 inhibitor, with an IC50 of 1.2 nM, and has antitumor activity.
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-120062
CAS No.: 2097262-58-1
Purity:  99.76%
Research Areas:  

Cancer

TVB-3664 is an orally available, reversible, potent, selective and highly bioavailable fatty acid synthase (FASN) inhibitor, with IC50 values of 18 nM and 12 nM for human and mouse cell palmitate synthesis, respectively. TVB-3664 significantly reduces tubulin palmitoylation and mRNA expression .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-16125
CAS No.: 187739-60-2
Synonyms: L-651582 Orotate; CAI Orotate
Carboxyamidotriazole Orotate (L-651582 Orotate) is the orotate salt form of Carboxyamidotriazole (CAI), an orally bioavailable signal transduction inhibitor. Carboxyamidotriazole Orotate is a cytostatic inhibitor of nonvoltage-operated calcium channels and calcium channel-mediated signaling pathways. Carboxyamidotriazole Orotate shows anti-tumor, anti-inflammatory and antiangiogenic effects .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-N1363
CAS No.: 14113-05-4
Synonyms: (E)-Queen Bee Acid; (E)-10-Hydroxy-2-decenoic acid
Royal Jelly Acid ((E)-Queen Bee Acid) is a major fatty acid found in royal jelly with oral bioavailability, exhibiting anti-inflammatory, anticancer, antimalarial, antiprotozoal, and neuroregulatory activities. Royal Jelly Acid can be used for research in various fields, including cancer, infections, immune inflammation, and neurological diseases .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-B0717
CAS No.: 9002-96-4
Synonyms: TPGS; D-α-Tocopherol polyethylene glycol 1000 succinate; Vitamin E-TPGS
Tocofersolan is synthetic polyethylene glycol derivative of α-tocopherol. Tocofersolan is an orally active and water-soluble analog of vitamin E. Tocofersolan can reduce neurobehavioral deficits in zebrafish embryos exposed to moderate and high concentrations of BaP during early development. Tocofersolan shows antioxidant activity. Tocofersolan can be used to provide an orally bioavailable source of vitamin E .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-10206
CAS No.: 850879-09-3
Purity:  99.40%
Synonyms: MP470; HPK 56
Research Areas:  

Cancer

Amuvatinib (MP470) is an orally bioavailable multi-targeted tyrosine kinase inhibitor with potent activity against mutant c-Kit, PDGFRα, Flt3, c-Met and c-Ret. Amuvatinib (MP470) is also a DNA repair suppressor through suppression of DNA repair protein RAD51, thereby disrupting DNA damage repair . Antineoplastic activity .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-P99340
CAS No.: 2423014-07-5
Synonyms: VIR 7831; GSK-4182136

Target:  

SARS-CoV

Research Areas:  

Infection Cancer

Sotrovimab (VIR 7831) is a human IgG1κ pan-sarbecovirus monoclonal antibody (mAb), neutralizes SARS-CoV-2, SARS-CoV-1, and multiple other sarbecoviruses. Sotrovimab is developed based on S309, exhibits a long half-life and great bioavailability in the respiratory mucosa. Sotrovimab could result in immune-mediated viral clearance and prevent progression of Covid-19 early in the course of disease .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-16961
CAS No.: 1123837-84-2
Synonyms: MGCD516; MG-516
Sitravatinib (MGCD516) is an orally bioavailable receptor tyrosine kinase (RTK) inhibitor with IC50s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DDR2, DDR1, TRKA, TRKB, respectively . Sitravatinib shows potent single-agent antitumor efficacy and enhances the activity of PD-1 blockade through promoting an antitumor immune microenvironment .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-15514A
CAS No.: 1206801-37-7
Purity:  99.36%
Synonyms: LY2801653 dihydrochloride
Research Areas:  

Cancer

Merestinib dihydrochloride (LY2801653 dihydrochloride) is a potent, orally bioavailable c-Met inhibitor (Ki=2 nM) with anti-tumor activities. Merestinib dihydrochloride also has potent activity against MST1R (IC50=11 nM), FLT3 (IC50=7 nM), AXL (IC50=2 nM), MERTK (IC50=10 nM), TEK (IC50=63 nM), ROS1, DDR1/2 (IC50=0.1/7 nM) and MKNK1/2 (IC50=7 nM) .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-15514
CAS No.: 1206799-15-6
Purity:  98.18%
Synonyms: LY2801653
Research Areas:  

Cancer

Merestinib (LY2801653) is a potent, orally bioavailable c-Met inhibitor (Ki=2 nM) with anti-tumor activities. Merestinib (LY2801653) also has potent activity against MST1R (IC50=11 nM), FLT3 (IC50=7 nM), AXL (IC50=2 nM), MERTK (IC50=10 nM), TEK (IC50=63 nM), ROS1, DDR1/2 (IC50=0.1/7 nM) and MKNK1/2 (IC50=7 nM) .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-10864
CAS No.: 546141-08-6
Purity:  99.15%
Synonyms: KDS-4103
Target:  

FAAH Autophagy Mitophagy

Research Areas:  

Neurological Disease

URB-597 (KDS-4103) is an orally bioavailable and selective FAAH inhibitor. URB-597 inhibits FAAH activity with an IC50s of approximately 5 nM in rat brain membranes, 0.5 nM in intact rat neurons, 3 nM in human liver microsomes. Antidepressant-like effects. Analgesic activity .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-109142
CAS No.: 1422500-60-4
Purity:  95.51%
Synonyms: AK0529; RO-0529
Target:  

RSV

Research Areas:  

Infection

Ziresovir (AK0529;RO-0529) is a potent, selective, and orally bioavailable respiratory syncytial virus (RSV) fusion (F) protein (RSV F) protein inhibitor. Ziresovir shows anti-RSV activity (EC50=3 nM) and highlights pharmacokinetics in animal species .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-15724
CAS No.: 698394-73-9
Purity:  98.26%
Synonyms: GSK-1605786; CCX282-B; Traficet-EN
Vercirnon (GSK1605786A) is an orally bioavailable, selective, and potent antagonist of CCR9. Vercirnon inhibits CCR9-mediated Ca 2+ mobilization and chemotaxis on Molt-4 cells with IC50 values of 5.4 and 3.4 nM, respectively. Vercirnon is selective for CCR9 over CCR1-12 and CX3CR1-7 (IC50s>10 μM for all). Vercirnon is an equipotent inhibitor of CCL25-directed chemotaxis of both splice forms of CCR9 (CCR9A and CCR9B) with IC50 values of 2.8 and 2.6 nM, respectively .
loading...
    loading...